[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606499":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":49,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":29,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":29,"enrollmentInfo":64,"targetDuration":29,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":29,"overallStatus":73,"whyStopped":29,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Yale University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Buprenorphine","EXPERIMENTAL","Participants will be offered weekly or monthly Buprenorphine injections",[13],"Drug: Buprenorphine",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Weekly or monthly extended-release subcutaneous injection",[9],[20],"BRIXADI",[22],{"name":23,"affiliation":5,"role":24},"Sandra Springer, MD","PRINCIPAL_INVESTIGATOR",[26,31],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","203-687-6680",null,"sandra.springer@yale.edu",{"name":32,"role":27,"phone":33,"phoneExt":29,"email":34},"Angela Di Paola","+1 475-306-1608","angela.dipaola@yale.edu",[36],{"facility":37,"status":29,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":29},"Yale School of Medicine","New Haven","Connecticut","06520","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-72.92816,41.30815,{"lat":47,"lon":46},{"type":50,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR",[52],{"name":53,"class":54},"Braeburn Pharmaceuticals","INDUSTRY","100606499","phase-4-acceptability-and-feasibility-of-extended-release-subcutaneous-buprenorphine-on-a-mobile-pharmacy-clinic-100606499",false,"NCT07176351","Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic","Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic: A Pilot Study","Inclusion Criteria:\n\n* Able to provide written informed consent in English or Spanish\n* Current or history of DSM-5 moderate-to-severe OUD per Rapid Opioid Use Disorder Assessment (ROUDA)\n* Not planning to move out of state or to new location during study enrollment.\n\nExclusion Criteria:\n\n* Medical or psychiatric disorders making participation unsafe or regular follow-up unlikely, (such as suicidal ideation or pre-existing moderate to severe hepatic impairment)\n* Persons who are pregnancy\n* People who show violent or threatening behavior toward staff and\u002For others\n* Allergy, hypersensitivity, or medical contraindication to medication (the BRIXADI needle cap is synthetically derived from natural rubber latex which may cause allergic reactions in persons with latex-sensitivity)","ALL","18 Years",{"count":65,"type":66},60,"ESTIMATED","INTERVENTIONAL",[69],"PHASE4","This exploratory project will assess the acceptability and feasibility of monthly extended-release subcutaneous buprenorphine (BRIXADI; XR-B) to treat opioid use disorder (OUD) among persons in the community receiving care on a mobile pharmacy clinic (MPC).\n\nParticipants who are interested in initiating monthly or weekly injections of subcutaneous XR-B (BRIXADI) as a treatment for their OUD will be enrolled in a 6-month study assessing the acceptability and feasibility of receiving XR-B on an MPC.",[72],"Opioid Use Disorder","NOT_YET_RECRUITING","2026-07-29",{"date":76,"type":77},"2026-07-31","ACTUAL",{"date":79,"type":66},"2026-08",{"date":81,"type":66},"2027-02",{"name":5,"class":6},1]